E2F7 is an atypical E2F transcription factor that functions primarily as a transcriptional repressor, binding DNA independently of DP proteins and recognizing canonical E2 recognition sites 1. In normal physiology, E2F7 plays critical roles in cell cycle regulation by repressing G1/S-regulated genes and acts as a downstream effector of p53-dependent DNA damage response by mediating repression of genes involved in DNA replication 2. E2F7 also regulates polyploidization in specialized tissues by antagonizing classical E2F proteins, essential for placental and hepatic development 3. Additionally, E2F7 suppresses ribosomal RNA gene transcription, linking cell cycle arrest to protein synthesis 1. In cancer contexts, E2F7 demonstrates dual functionality. In small-cell lung cancer, RB1 mutations recruit E2F7-RCOR co-repressor complexes to silence YAP expression, promoting metastasis 4. E2F7 upregulation in hypoxic esophageal cancer activates QKI to promote circBCAR3 biogenesis, driving tumorigenesis 5. In anaplastic thyroid cancer, E2F7 drives aggressive features through cell cycle and DNA repair programs 6. Conversely, in gastric cancer, E2F7 represses MYBL2 to inhibit proliferation 7, while in hepatocellular carcinoma, E2F7-mediated MT2P1 suppression promotes cancer progression 3. E2F7 loss also confers PARP inhibitor resistance through altered BRCA2 expression in prostate cancer 8. These findings indicate E2F7's context-dependent roles in cancer progression, making it a potential therapeutic target.